10:30 AM EST - Fennec Pharmaceuticals Inc. : Announced today the results presented at the 2016 ASCO meeting in Chicago on June 5. Penelope Brock, M.D., PhD, International Chair of SIOPEL, presented the "Two-year results of clinical efficacy of cisplatin in combination with sodium thiosulfate (STS) vs cisplatin alone in a randomized phase III trial for standard risk hepatoblastoma (SR-HB)." Fennec Pharmaceuticals Inc.
shares T.FRX are trading unchanged at $3.12.
